Physiomics signs agreement with Cancer Research UK
Virtual tumour software developer Physiomics signed an agreement to with Bicycle Therapeutics and Cancer Research UK on Monday.
FTSE AIM All-Share
755.44
09:05 26/04/24
Health Care Equipment & Services
11,785.09
08:39 26/04/24
Physiomics
1.50p
16:55 25/04/24
The collaborative project is expected to be completed during this calendar year and will focus on the analysis of clinical data arising from the ongoing Cancer Research UK-sponsored Phase I/IIa clinical trial of Bicycle Therapeutics' lead program, BT1718, in solid tumours.
Jim Millen, chief executive of Physiomics, said: "We are very pleased to be working on this second project with Bicycle Therapeutics and to be working for the first time directly with Cancer Research UK, the UK's leading cancer research charity."
Physiomics' shares were up 1.31% at 3.09p at 1255 BST.